JP2021535163A5 - - Google Patents

Info

Publication number
JP2021535163A5
JP2021535163A5 JP2021511544A JP2021511544A JP2021535163A5 JP 2021535163 A5 JP2021535163 A5 JP 2021535163A5 JP 2021511544 A JP2021511544 A JP 2021511544A JP 2021511544 A JP2021511544 A JP 2021511544A JP 2021535163 A5 JP2021535163 A5 JP 2021535163A5
Authority
JP
Japan
Prior art keywords
composition
composition according
taurinamide
taurartum
once
Prior art date
Application number
JP2021511544A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020047113A5 (https=
JP2021535163A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/048592 external-priority patent/WO2020047113A1/en
Publication of JP2021535163A publication Critical patent/JP2021535163A/ja
Publication of JP2021535163A5 publication Critical patent/JP2021535163A5/ja
Publication of JPWO2020047113A5 publication Critical patent/JPWO2020047113A5/ja
Priority to JP2024154822A priority Critical patent/JP2024170590A/ja
Pending legal-status Critical Current

Links

JP2021511544A 2018-08-28 2019-08-28 タウロリジン加水分解産物による神経芽細胞腫治療 Pending JP2021535163A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024154822A JP2024170590A (ja) 2018-08-28 2024-09-09 タウロリジン加水分解産物による神経芽細胞腫治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862723618P 2018-08-28 2018-08-28
US62/723,618 2018-08-28
PCT/US2019/048592 WO2020047113A1 (en) 2018-08-28 2019-08-28 Neuroblastoma treatment with taurolidine hydrolysis products

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024154822A Division JP2024170590A (ja) 2018-08-28 2024-09-09 タウロリジン加水分解産物による神経芽細胞腫治療

Publications (3)

Publication Number Publication Date
JP2021535163A JP2021535163A (ja) 2021-12-16
JP2021535163A5 true JP2021535163A5 (https=) 2022-08-30
JPWO2020047113A5 JPWO2020047113A5 (https=) 2022-08-30

Family

ID=69645349

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021511544A Pending JP2021535163A (ja) 2018-08-28 2019-08-28 タウロリジン加水分解産物による神経芽細胞腫治療
JP2024154822A Pending JP2024170590A (ja) 2018-08-28 2024-09-09 タウロリジン加水分解産物による神経芽細胞腫治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024154822A Pending JP2024170590A (ja) 2018-08-28 2024-09-09 タウロリジン加水分解産物による神経芽細胞腫治療

Country Status (7)

Country Link
EP (1) EP3843746A4 (https=)
JP (2) JP2021535163A (https=)
KR (1) KR20210050544A (https=)
CN (1) CN113347976A (https=)
AU (1) AU2019330954B2 (https=)
CA (1) CA3111057A1 (https=)
WO (1) WO2020047113A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113226325A (zh) * 2018-08-31 2021-08-06 科医公司 牛磺罗定对哺乳动物体内表达myc的肿瘤的治疗
CA3140981A1 (en) * 2019-05-22 2020-11-26 Geistlich Pharma Ag Oxathiazin compounds for inhibiting gapdh
CN116769723B (zh) * 2023-08-09 2023-11-03 山东省成体细胞产业技术研究院有限公司 一种gd2嵌合抗原受体修饰的t细胞及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602150A (en) * 1992-10-02 1997-02-11 Research Foundation For Mental Hygiene, Inc. Treatment of central nervous system disorders associated with psychotic behavior and dementia with a combination of neuroleptic drugs and taurine, or derivatives thereof, to prevent the development of tardive dyskinesia
US20030027818A1 (en) * 2001-04-03 2003-02-06 Redmond H. Paul Treatment of cancers
US20050096314A1 (en) * 2001-04-03 2005-05-05 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
CN100519525C (zh) * 1999-12-06 2009-07-29 葛兰素集团有限公司 芳香砜类及其医疗用途
JP5027369B2 (ja) * 1999-12-06 2012-09-19 ガイストリッヒ ファーマ アーゲー 腫瘍を治療する方法
CA2363973C (en) * 2000-11-28 2009-03-10 Ed. Geistlich Sohne Ag Fur Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
ATE354380T1 (de) * 2003-02-03 2007-03-15 Polaschegg Hans-Dietrich Dr Te Zusammensetzung zur prävention von infektionen durch subkutane prothesen
US20080177217A1 (en) * 2004-05-14 2008-07-24 Hans-Dietrich Polaschegg Taurolidine Formulations and Delivery: Therapeutic Treatments and Antimicrobial Protection Against Bacterial Biofilm Formation
ES2377206T3 (es) * 2006-01-06 2012-03-23 Ed Geistlich Sohne Ag Fur Chemische Industrie Composiciones irradiadas y tratamiento de cánceres con radiación en combinación con taurolidina y/o taurultam
CN103118669B (zh) * 2010-06-01 2016-01-13 盖斯特里希医药公司 口服药物治疗方法和组合物
WO2013148912A1 (en) * 2012-03-30 2013-10-03 Novartis Ag Compounds for use in the treatment of neuroblastoma, ewing's sarcoma or rhabdomyosarcoma
EP3402527B1 (en) * 2016-01-11 2022-09-28 CorMedix Inc. Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers

Similar Documents

Publication Publication Date Title
EP4631571A3 (en) Combination of dextromethorphan and bupropion for treating depression
FI3426285T3 (fi) Pegyloidun urikaasin formulaatioita ja annoksia
WO2003039436A3 (es) Composiciones farmaceuticas que contienen oxibutinina
JP2004508404A5 (https=)
DK1453487T3 (da) Farmaceutisk doseringsform med flere belægninger for reduceret virkning af belægningsbrud
JP2020516646A5 (https=)
JP2021535163A5 (https=)
WO2021062282A1 (en) Combination therapy with cgrp antagonists
KR20140025314A (ko) 복합 조성물
WO2002089805A2 (en) Use of regularly scheduled high dose intravenous methotrexate therapy
MX2024010637A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
RU2005126819A (ru) Усовершенствованное лечение опухолей
JP2008540364A5 (https=)
JP2025148449A5 (https=)
JP2016505050A5 (https=)
JP2019506397A5 (https=)
FI3359572T3 (fi) Menetelmä multippeliskleroosin hoitamiseksi
MX2024006270A (es) Nueva composicion farmaceutica oral y regimen de dosificacion para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas.
JP2019509309A5 (https=)
FI4255563T3 (fi) 5’-o-fenyyliasetyyliuridiini ja terapeuttinen käyttö
JPWO2020047113A5 (https=)
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
CN114073698B (zh) 一种止痛止痒药物组合物及其应用方法
JP2021535167A5 (https=)
JP2021535173A5 (https=)